FT LAUDERDALE, FL--(Marketwire - March 23, 2009) - LYFETEC, Inc. (PINKSHEETS: TSHL) listed
under new CUSIP 55084L 10 6, has finalized its exclusive license contract
with Intellect Laboratories, Inc. for a comprehensive line of drug testing
and screening products and services. The line will be enhanced by
Intellect and private branded such that LyfeTec will be a sole source
The products and services will soon be offered by LyfeTec to specific
existing and new distributors in several countries. Two different product
categories exist within the set of twelve (12) tests, one set targeted for
over the counter markets and another focused at professional and corporate
use. A unique packaging and tracking system with associated identity
protection software makes the LyfeTec products unique in the industry and
an attractive complement to its growing line.
The tests consist of eleven (11) specific drug screening tests that use
saliva and urine to accurately and definitively detect drug presence,
offering immediate results to the user. Results are provided in a new way
to assure strict confidentiality for the user. For a small additional
price, the specimen(s) can be sent into one of LyfeTec's affiliate labs for
independent verification of results in writing -- an important unfulfilled
need in this industry. LyfeTec believes that this dual results approach
coupled with the first-to-market confidentiality software controls will
increase customer reliance on the LyfeTec products thereby providing a
considerable competitive advantage to the company.
The last product in the set consists of a unique screening kit for
uncovering tobacco use. This product is seen by LyfeTec marketing as an
important one because insurance companies, plastic surgeons, employers,
parents and so forth need to reliably know if an individual uses tobacco.
As with all of the screening products described, the tobacco screening test
provides instant, confidential results.
Safe Harbor Act Disclaimer: Forward-looking statements in this release are
made pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to certain risks, and uncertainties and actual results could differ from
those discussed. This material is information only and is not an offer or
solicitation to buy or sell the securities.